Samaritan acquires rights to Abiogens cancer drug

Pharmaceutical Business Review: "Abioklad is used for the treatment of cancer malignancy-associated hypercalcemia (high blood calcium), the inhibition of osteolysis (degeneration of bone tissue), and the decrease of bone pain associated with cancer. Discovered by Abiogen Pharma, Abioklad is a bisphosphonate that binds to calcium and inhibits osteoclastic bone resorption, crystal formation, and dissolution, resulting in a reduction of bone turnover."